Annovis Bio
Berwyn
About Annovis Bio
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $105.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nysemkt:ANVS
- Website: annovisbio.com
- Phone: (610)727-3913
Industries & Categories
Biotechnology, Developer Platform, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/annovis-bio-9169 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.